The use of Tocilizumab in a case of Biologic-Refractory Antisynthetase Syndrome

Sean M. Murphy; James B. Lilleker; Hector Chinoy; Philip Helliwell

doi:10.1093/rheumatology/kew131

The use of Tocilizumab in a case of Biologic-Refractory Antisynthetase Syndrome

Sean M. Murphy, James B. Lilleker, Hector Chinoy, Philip Helliwell

Division of Musculoskeletal & Dermatological Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Antisynthetase syndrome (ASS) is a connective tissue disease consisting of myositis, interstitial lung disease, arthritis, Raynaud’s phenomenon, mechanics’ hands and serum anti-aminoacyl-tRNA synthetase antibodies. Despite standard treatment of corticosteroids and immunosuppressive therapy, ASS can remain active in a significant proportion of cases. We report a case of refractory ASS where tocilizumab (an IL-6 receptor blocking monoclonal antibody) was used with beneficial effect.

Original language	English
Pages (from-to)	63-63
Journal	Rheumatology
Volume	55
DOIs	https://doi.org/10.1093/rheumatology/kew131
Publication status	Published - Apr 2016

Access to Document

10.1093/rheumatology/kew131

Cite this

@article{dcd1ad0720554cee99904dec41f427b1,

title = "The use of Tocilizumab in a case of Biologic-Refractory Antisynthetase Syndrome",

abstract = "Antisynthetase syndrome (ASS) is a connective tissue disease consisting of myositis, interstitial lung disease, arthritis, Raynaud{\textquoteright}s phenomenon, mechanics{\textquoteright} hands and serum anti-aminoacyl-tRNA synthetase antibodies. Despite standard treatment of corticosteroids and immunosuppressive therapy, ASS can remain active in a significant proportion of cases. We report a case of refractory ASS where tocilizumab (an IL-6 receptor blocking monoclonal antibody) was used with beneficial effect.",

author = "Murphy, {Sean M.} and Lilleker, {James B.} and Hector Chinoy and Philip Helliwell",

year = "2016",

month = apr,

doi = "10.1093/rheumatology/kew131",

language = "English",

volume = "55",

pages = "63--63",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - The use of Tocilizumab in a case of Biologic-Refractory Antisynthetase Syndrome

AU - Murphy, Sean M.

AU - Lilleker, James B.

AU - Chinoy, Hector

AU - Helliwell, Philip

PY - 2016/4

Y1 - 2016/4

N2 - Antisynthetase syndrome (ASS) is a connective tissue disease consisting of myositis, interstitial lung disease, arthritis, Raynaud’s phenomenon, mechanics’ hands and serum anti-aminoacyl-tRNA synthetase antibodies. Despite standard treatment of corticosteroids and immunosuppressive therapy, ASS can remain active in a significant proportion of cases. We report a case of refractory ASS where tocilizumab (an IL-6 receptor blocking monoclonal antibody) was used with beneficial effect.

AB - Antisynthetase syndrome (ASS) is a connective tissue disease consisting of myositis, interstitial lung disease, arthritis, Raynaud’s phenomenon, mechanics’ hands and serum anti-aminoacyl-tRNA synthetase antibodies. Despite standard treatment of corticosteroids and immunosuppressive therapy, ASS can remain active in a significant proportion of cases. We report a case of refractory ASS where tocilizumab (an IL-6 receptor blocking monoclonal antibody) was used with beneficial effect.

U2 - 10.1093/rheumatology/kew131

DO - 10.1093/rheumatology/kew131

M3 - Article

SN - 1462-0324

VL - 55

SP - 63

EP - 63

JO - Rheumatology

JF - Rheumatology

ER -

The use of Tocilizumab in a case of Biologic-Refractory Antisynthetase Syndrome

Abstract

Access to Document

Fingerprint

Cite this